Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid
The last two decades have witnessed a substantial increase in the incidence of bullous pemphigoid (BP) worldwide.1 One of the most compelling interpretations accounting for this epidemiological observation is the growing exposure to novel drug classes that might be implicated in eliciting the disease.1 Multiple lines of evidence have recently accumulated to suggest that exposure to dipeptidyl peptidase 4 (DPP4) inhibitors and checkpoint inhibitors (CPIs) is associated with an elevated risk of BP.2,3 As these drugs were introduced only in the past two decades, their rising utilization underlies, at least in part, the growing incidence of BP.1
Preview
Rights
Use and reproduction:
Please note that individual components of the publication may be subject to other licensing or copyright conditions.